Laserscope Sets Niagara BPH System Annual Sales Target Of $90 Mil. By 2006
This article was originally published in The Gray Sheet
Executive SummaryLaserscope aims to generate up to $90 mil. in annual sales of its Niagara PVP laser treatment system for benign prostatic hyperplasia (BPH) by 2006
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.